SWOG clinical trial number
S0517

A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma -

77% Accrual
Accrual
77%
Closed
Phase
77% Accrual
Accrual
77%
Published
Abbreviated Title
HODGKIN'S: SAHA for Recurrent or Primary Refractory Hodgkin's Lymphoma
Activated
09/15/2005
Closed
08/01/2007
Participants
NCORP, Members, Medical Oncologists, Affiliates

Research committees

Lymphoma

Treatment

Suberoylanilide Hydroxamic Acid (SAHA; Vorinostat)

Other Clinical Trials

S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
21% Accrual
Accrual
21%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number